Peptides – shipping from Europe

Research Disclaimer: This article is intended for educational and informational purposes regarding the chemical and biochemical properties of research compounds. All information is provided strictly in a scientific context. This content does not constitute medical advice, nor does it promote the use of any compound for human or veterinary application. All compounds referenced are for laboratory research use only.

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a peptide engineered to mimic and extend the activity of the endogenous incretin hormone GLP-1 while resisting the rapid enzymatic degradation that limits native GLP-1’s duration of action. It represents one of the more successful examples of rational peptide drug design: a molecule deliberately modified at three structural points to achieve pharmacokinetic properties that would be impossible with the unmodified hormone.

For researchers working with GLP-1 receptor biology, studying incretin physiology, or investigating the pharmacology of this compound class, understanding semaglutide’s structure and the history of its development provides essential context.

Classification: GLP-1 Receptor Agonists

Semaglutide belongs to the class of GLP-1 receptor agonists (GLP-1RAs), a group of peptides that bind and activate the GLP-1 receptor (GLP-1R) — a class B G protein-coupled receptor (GPCR) expressed in pancreatic beta cells, the hypothalamus, brainstem, stomach, heart, kidney, and liver. Activation of GLP-1R by semaglutide reproduces and amplifies the pharmacological effects of native GLP-1: glucose-dependent enhancement of insulin secretion, suppression of glucagon, slowing of gastric emptying, and activation of hypothalamic satiety circuits.

Within the GLP-1RA class, compounds are distinguished by their structural basis — some are exendin-4-based (derived from Gila monster venom), and others are human GLP-1-based. Semaglutide is human GLP-1-based, sharing approximately 94% sequence identity with native human GLP-1(7-37).

The Native GLP-1 Starting Point

Native GLP-1, in its biologically active form, is a 30-amino acid peptide designated GLP-1(7-36) amide or GLP-1(7-37) depending on the C-terminal processing. It is produced by proglucagon-expressing L-cells in the distal small intestine and colon, released postprandially in response to nutrient sensing, and has a plasma half-life of approximately 1–2 minutes due to rapid DPP-4 cleavage at the N-terminus and renal filtration.

This extremely short half-life makes native GLP-1 pharmacologically impractical as a therapeutic or research tool requiring sustained receptor engagement. The development of semaglutide was driven by the goal of maintaining the full pharmacological activity of GLP-1 while overcoming this rapid inactivation.

Molecular Structure of Semaglutide

The Three Engineering Decisions

1. Position 8 Substitution: DPP-4 Resistance

The most critical modification for pharmacokinetic extension is the substitution of the naturally occurring alanine at position 8 of the GLP-1 sequence (the second residue from the N-terminus of the active peptide) with alpha-aminoisobutyric acid (Aib). DPP-4 is an ubiquitous serine protease that cleaves peptides after a penultimate N-terminal residue, with strong preference for alanine or proline at that position.

Aib is a non-natural alpha-methyl amino acid that creates steric hindrance at the cleavage site without abolishing receptor binding. DPP-4 cannot efficiently process the Aib-containing peptide, and this single substitution increases the peptide’s enzymatic stability from minutes to days. This modification was first explored in the development of earlier GLP-1 analogues and was carried forward into semaglutide’s design.

2. Position 34 Substitution: Directing Fatty Acid Attachment

Native GLP-1 has a lysine residue at position 26 and position 34. The fatty acid modification is intended to attach specifically at position 26. If Lys34 were retained, the fatty acid chain could attach at either lysine during synthesis, producing a mixture of regioisomers with different pharmacological properties.

Replacing Lys34 with Arg34 (arginine does not carry a primary amine that would react with the fatty acid coupling chemistry under the synthesis conditions used) ensures that the fatty acid modification attaches exclusively at Lys26. This substitution is a synthetic chemistry necessity rather than a direct pharmacological design choice.

3. Lys26 Fatty Acid Chain: Albumin Binding and Renal Protection

The most structurally distinctive feature of semaglutide is the C18 fatty diacid chain attached to the epsilon-amino group of Lys26 via a hydrophilic linker consisting of two mini-polyethylene glycol (mini-PEG) spacers and two gamma-glutamic acid residues. This modification was designed to enable non-covalent, reversible binding to serum albumin.

Serum albumin (molecular weight ~67 kDa) is the most abundant plasma protein and has a well-characterised fatty acid binding site. By carrying a fatty acid chain, semaglutide can occupy this site, binding albumin reversibly. Albumin’s large molecular size prevents glomerular filtration (the renal threshold is approximately 70 kDa), and albumin has a long circulatory half-life (~19 days). When semaglutide is albumin-bound, it inherits these properties — it is protected from renal clearance and circulates with albumin’s extended lifetime.

The binding is non-covalent and reversible: at equilibrium, a small fraction of semaglutide is unbound (free) and pharmacologically active, while the majority is albumin-bound and pharmacologically protected. The unbound fraction activates GLP-1R and exerts the pharmacological effects; as free semaglutide is consumed or cleared, more is released from albumin to maintain activity. This reservoir mechanism is what supports once-weekly dosing.

Research History and Development

The development of GLP-1-based therapeutics traces back to the foundational incretin biology research of the 1980s and 1990s. Jens Juul Holst at the University of Copenhagen characterised GLP-1 as the dominant incretin hormone in the late 1980s. Joel Habener at Massachusetts General Hospital and Daniel Drucker at the University of Toronto contributed to establishing the pharmacological properties of GLP-1R activation.

Novo Nordisk’s peptide engineering programme developed semaglutide through systematic optimisation of earlier GLP-1 analogues. The specific combination of DPP-4-resistant backbone modification, albumin-binding fatty acid chain, and optimised linker chemistry that defines semaglutide represents a cumulative series of design decisions refined through iterative medicinal chemistry work. Semaglutide was first described in the scientific literature in 2012, with initial pharmacokinetic data confirming the ~7-day half-life in human subjects.

Research-Grade Semaglutide

Research-grade semaglutide is synthesised by solid-phase peptide synthesis (SPPS), incorporating the same sequence modifications — Aib at position 8, Arg at position 34, and the C18 fatty diacid chain at Lys26 — as the pharmaceutical product. Verification by HPLC and high-resolution mass spectrometry is essential for research-grade material, as the fatty acid-linked structure is complex and presents more potential for synthesis impurities than simpler linear peptides.

The identical molecular structure between research-grade and pharmaceutical semaglutide means that research conducted with verified, pure research-grade material is directly pharmacologically relevant to understanding the compound’s biology.

ℹ️ Semaglutide is a pharmaceutical compound approved for clinical use under prescription. This article describes its structure and research background for scientific reference. Research-grade semaglutide is supplied for laboratory research use only.

Semaglutide GLP-1 is available in research-grade, lyophilized form from the Aminopept research catalogue. Supplied for laboratory and in-vitro research use only.

→ View GLP-1 in the research catalogue